LIPANTIL Capsule Ref.[49984] Active ingredients: Fenofibrate

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2020  Publisher: Mylan Products Ltd., 20 Station Close, Potters Bar, Herts, EN6 1TL, United Kingdom

4.1. Therapeutic indications

Lipantil Micro 67mg is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following:

  • Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol.
  • Mixed hyperlipidaemia when a statin is contraindicated or not tolerated.
  • Mixed hyperlipidaemia in patients at high cardiovascular risk in addition to a statin when triglycerides and HDL cholesterol are not adequately controlled.

4.2. Posology and method of administration

Dietary measures initiated before therapy should be continued. Response to therapy should be monitored by determination of serum lipid values. If an adequate response has not been achieved after several months (e.g. 3 months), complementary or different therapeutic measures should be considered.

Posology

Adults

The recommended dose is 200mg daily administered as three capsules of Lipantil Micro 67mg.

The dose can be titrated up to 267mg daily administered as 4 capsules of Lipantil Micro 67mg, if required. This maximum dose is not recommended in addition to a statin.

Special populations

Elderly patients (≥65 years old)

No dose adjustment is necessary. The usual dose is recommended, except for decreased renal function with estimated glomerular filtration rate <60 mL/min/1.73 (see Patients with renal impairment).

Patients with renal impairment

Fenofibrate should not be used if severe renal impairment, defined as eGFR <30 mL/min per 1.73 m², is present. If eGFR is between 30 and 59 mL/min per 1.73 m², the dose of fenofibrate should not exceed 100 mg standard or 67 mg micronized once daily. If, during follow-up, the eGFR decreases persistently to <30 mL/min per 1.73 m², fenofibrate should be discontinued.

Hepatic impairment

Lipantil Micro 67mg is not recommended for use in patients with hepatic impairment due to the lack of data.

Paediatric population

In children, the recommended dose is one capsule (67mg) micronised fenofibrate/day/20kg body weight (see section 4.4).

Method of administration

Capsules should be swallowed whole during a meal.

4.9. Overdose

Only anecdotal cases of fenofibrate overdosage have been received. In the majority of cases no overdose symptoms were reported.

No specific antidote is known. If overdose is suspected, treat symptomatically and institute appropriate supportive measures as required. Fenofibrate cannot be eliminated by haemodialysis.

6.3. Shelf life

3 years.

6.4. Special precautions for storage

Store in the original package. Do not store above 30°C.

6.5. Nature and contents of container

Pack of 28, 56, 84, 90 capsules in blisters (PVC/Aluminium).

* Not all pack sizes may be marketed.

6.6. Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.